作为吉林省梅花鹿产业龙头企业，吉林敖东在"十五五"期间将进一步强化鹿茸产业的核心竞争力，以全 产业链闭环管理守护中药瑰宝的纯正与安全。公司自主培育的"敖东梅花鹿"作为国内首个以企业命名的 国家级梅花鹿品种，从遗传根源锁定了原料的纯正性与优良性状。在长白山核心产区，超350公顷的 GAP 标准化养殖基地持续扩容提质，梅花鹿存栏量稳定在近3000头，延续传统自然采食方式，确保鹿 茸原料的天然品质。为筑牢安全防线，公司累计投入超4600万元升级防疫设施，通过迁移职工家属区划 定隔离缓冲带等极致管控措施，自 2021年起连续保持布病与结核病零阳性纪录，实现鹿茸原料"全流程 闭环管理"，所有优质资源均锁定在自有体系内，从源头保障了中药材品质。 "全产业链布局不仅是品质'护城河'，也是抵御成本波动、践行社会责任的'稳定器'" 。吉林敖东表示， 公司将在"十五五"期间持续深化产业优势，以规模效应摊薄固定成本、增强产业链议价能力；企业将始 终以提升产品内在质量标准为核心，构建可持续的价值生态，用实际行动回馈消费者与投资者的信任。 依托优质鹿茸原料，吉林敖东在"十五五"期间将持续发力产品集群建设，以安神补脑液为核心的鹿系列 产 ...

本次药品捐赠聚焦当地群众卫生健康需求，涵盖了包括对乙酰氨基酚泡腾片、氨咖黄敏胶囊、复方氨酚烷胺片、复方金银 花颗粒在内的4类急需常用药品，总价值人民币59.49万元。这些药品将精准发放至1147户农牧民家庭，有效补充基层医疗卫生 资源，为当地村民的健康保驾护航。 在为基层群众送去健康保障的同时，吉林敖东也始终锚定中医药传承创新的发展方向，稳步推进产业升级。在中医药传承 创新的浪潮中，吉林敖东以科技创新为核心引擎，以标准建设为重要抓手，走出了一条兼具传统特色与现代气息的中医药产业 发展之路。 在科技创新层面，吉林敖东聚焦中药材核心物质基础研究，布局抗衰与再生医学前沿领域，推动中医药从"经验传 承"向"科学解码"跨越。吉林敖东深度挖掘传统中药材的现代科研价值，其相关研究证实，部分中药材活性成分在抗衰、神经 保护、骨骼修复等方面展现出巨大潜力。依托这些研究成果，吉林敖东成功斩获两项重磅发明专利，推动核心产品从传统功效 定位，升级至前沿赛道，精准对接高品质健康消费需求。 同时，吉林敖东以新质生产力赋能中医药全产业链智能化升级。在产业链前端，运用分子辅助育种等生物技术优化药材种 源性状，引入智能化管理系统，实现种植、养 ...

Core Viewpoint - Jilin Aodong's Anshen Bnona Liquid has maintained a leading position in the domestic market for over 42 years, achieving cumulative sales of 8 billion bottles and a market share exceeding 80% [1][12] Group 1: Product Quality and Market Position - Anshen Bnona Liquid is recognized as a core product of Jilin Aodong, generating a total profit of 2.1 billion yuan and contributing 1.5 billion yuan in taxes to the state [1] - The product has been included in the first batch of protected traditional Chinese medicine varieties and the national medical insurance catalog, highlighting its significance in the industry [1][8] - The product's success is attributed to the use of high-quality, authentic medicinal materials sourced from the Changbai Mountain region, particularly the purebred velvet antler from the local deer [2][3] Group 2: Technological Innovation and Quality Control - Jilin Aodong has implemented modern production techniques, resulting in a 15% higher content of active ingredients like uridine and IGF-1 compared to ordinary deer antler [3][6] - The company has developed advanced technologies such as computer-controlled extraction and near-infrared online detection, ensuring product safety and consistency [6][8] - Continuous research and development efforts have led to the enhancement of production processes and quality standards, including the addition of new testing methods for raw materials [7][10] Group 3: Strategic Development and Policy Support - The company is positioned as a leading enterprise in the agricultural industrialization of Jilin Province, benefiting from government support for the development of the velvet antler industry [11] - Recent provincial policies encourage the secondary development of classic formulas and emphasize quality certification, aligning with Jilin Aodong's strategic goals [11] - The company aims to transform Anshen Bnona Liquid into a "ten billion-level product" by leveraging its market foundation and scientific breakthroughs [10][11]

Core Viewpoint - Jilin Aodong has evolved into a holding group company driven by both the pharmaceutical industry and financial capital, aiming to rejuvenate traditional Chinese medicine in modern society through innovation [6][13]. Company Development - Founded in 1957, Jilin Aodong has undergone significant transformations, including the establishment of a pharmaceutical factory in 1981, a shareholding reform in 1993, and its listing on the Shenzhen Stock Exchange in 1996 [6]. - The company has developed a comprehensive industrial chain in the pharmaceutical sector, integrating cultivation, research, production, testing, and sales [7]. Product Innovation - Jilin Aodong's core product, "Anshen Bnuna Liquid," has been a market leader for over 40 years, with a market share of 60% to 70% in its category, generating over 700 million yuan in annual sales [7]. - The company has a diverse product portfolio with 628 drug approval numbers, including 47 exclusive varieties, and has completed the listing of 525 traditional Chinese medicine formula granules [9]. Technological Advancements - The company has invested 1 billion yuan in an automated production line for traditional Chinese medicine extraction, set to be operational by the end of 2024, with an annual extraction capacity of 5,000 tons [10]. - The production process has transitioned to a fully automated system, enhancing efficiency and precision in drug manufacturing [10]. Market Expansion - Jilin Aodong is expanding into the health industry, producing over 200 health products, with some individual products generating over 1 million yuan in annual sales [11]. - The company is also investing in financial sectors, with a reported investment income of 1.206 billion yuan in the first half of 2025, a 53.67% increase year-on-year [12]. Financial Performance - In the first half of 2025, Jilin Aodong achieved a net profit of 1.282 billion yuan, a significant increase of 138.44% compared to the previous year [12]. - The company's total assets reached 34.151 billion yuan, with a debt-to-asset ratio of 11.54%, indicating a strong financial position [12]. Social Responsibility - Jilin Aodong has distributed 4.505 billion yuan in cash dividends over 17 years and has contributed to local economic development through agricultural projects, generating 7.76 billion yuan in output value over the past decade [12].

Core Viewpoint - Jilin Aodong aims to transform traditional Chinese medicine into a modern enterprise through innovation and sustainable development, establishing itself as a leading pharmaceutical company with a dual focus on "pharmaceutical health + financial capital" [2][9]. Group 1: Company History and Development - Jilin Aodong has evolved from a state-owned deer farm established in 1957 to a publicly listed holding company, with significant milestones including the founding of a pharmaceutical factory in 1981 and its listing on the Shenzhen Stock Exchange in 1996 [2]. - The company has developed a comprehensive industrial chain in deer product processing, leveraging over 60 years of experience in breeding deer and achieving GAP certification for its breeding base [3]. Group 2: Product and Market Position - Jilin Aodong's core product, "Anshen Bunan Liquid," has been a market leader for over 40 years, holding a 60% to 70% market share in its category and generating over 700 million yuan in annual sales [3][8]. - The company has a diverse product portfolio with 628 drug approval numbers, including 47 exclusive varieties, and has completed the registration of 525 traditional Chinese medicine formula granules, leading in registration numbers in Jilin Province [5]. Group 3: Innovation and Technology - Jilin Aodong has invested 1 billion yuan in an automated production line for traditional Chinese medicine extraction, set to be operational by the end of 2024, with an annual extraction capacity of 5,000 tons [6]. - The company is embracing digital transformation, moving from experience-based production to data-driven processes, enhancing efficiency and product quality [6]. Group 4: Financial Performance - In the first half of the year, Jilin Aodong reported a net profit of 1.282 billion yuan, a significant increase of 138.44% year-on-year, with total assets reaching 34.151 billion yuan, up 3.48% from the beginning of the year [8]. - The company maintains a low debt ratio of 11.54%, indicating strong financial health within the industry [8]. Group 5: Social Responsibility and Community Engagement - Jilin Aodong has distributed 4.505 billion yuan in cash dividends over 17 years and has created significant economic value for local communities through initiatives in ginseng and deer farming, generating 7.76 billion yuan in output value over the past decade [9]. - The company emphasizes its commitment to reinvesting profits into its pharmaceutical core business to support research, production upgrades, and market expansion [9].

Core Viewpoint - Jilin Aodong Pharmaceutical Group Co., Ltd. reported a significant increase in net profit despite a decline in revenue, demonstrating strong operational capabilities and strategic execution [1][4]. Financial Performance - In the first half of 2025, the company achieved operating revenue of 1.126 billion yuan, a year-on-year decrease of 20.21% - The net profit attributable to shareholders reached 1.282 billion yuan, a year-on-year increase of 138.44% [1]. Business Structure - The traditional Chinese medicine segment remains the core business, generating sales revenue of 686 million yuan, accounting for 60.90% of total revenue - The chemical drugs, chain pharmacy wholesale and retail, and health industry segments contributed sales revenues of 143 million yuan, 187 million yuan, and 83 million yuan, representing 12.73%, 16.59%, and 7.39% of total revenue, respectively [1]. Strategic Initiatives - The company is actively reforming its marketing system in the traditional Chinese medicine segment, having completed the marketing restructuring of 22 products and adjusted pricing policies for over 50 products - The company has made significant progress in its Chinese medicine formula granule business, obtaining 525 registration certificates for market access [2]. - A plan to issue convertible bonds to raise 134 million yuan for capital increase in its subsidiary, aimed at constructing a project for Chinese medicine formula granules with an annual production capacity of 2,000 tons [2]. Market Trends - The recovery of the consumer market is expected to accelerate the sales of consumer-oriented traditional Chinese medicine - Long-term growth is supported by an aging population and increasing health awareness among residents, providing a solid foundation for the industry [3]. Operational Efficiency - The company has optimized operational efficiency and adjusted regional layouts by closing some chain pharmacy stores, while enhancing brand management and deepening industry chain collaboration - The chain pharmacy business added 73,000 new members during the reporting period [3]. Asset Management - As of June 30, 2025, the company reported total assets of 34.151 billion yuan, a 3.48% increase from the beginning of the year, and net assets of 29.960 billion yuan, a 3.21% increase - The asset-liability ratio stands at 11.54%, indicating a low level within the industry [4].

Core Viewpoint - The traditional Chinese medicine (TCM) sector is experiencing significant opportunities due to favorable policies and market developments, with a notable surge in stock performance among TCM companies [6][9]. Market Performance - On August 1, the A-share market saw a slight decline, with the Shanghai Composite Index down 0.37%, Shenzhen Component Index down 0.17%, and ChiNext Index down 0.24%. However, over 3,300 stocks rose in the market [1][2]. - The TCM sector led the market with a substantial increase, as evidenced by the 1.78% rise in the Shenwan TCM Index, with several companies, including Weikang Pharmaceutical and Tianmu Pharmaceutical, hitting the daily limit [5][6]. Policy and Industry Developments - The establishment of the Yangtze River Delta TCM Concept Verification and Achievement Transformation Center in Shanghai aims to enhance the commercialization of TCM research and development [6]. - The State Council's 2025 directive emphasizes the protection and utilization of TCM resources, indicating a supportive regulatory environment for the industry [6]. Company Performance - Notable TCM companies reported significant profit growth in the first half of 2025. For instance, Darentang's net profit is expected to reach between 18.4 billion to 20 billion yuan, marking a year-on-year increase of 180% to 204% [9][11]. - Jilin Aodong anticipates a net profit of approximately 12.36 billion to 12.9 billion yuan, reflecting a year-on-year growth of 130% to 140% [9][11]. - Tianmu Pharmaceutical successfully turned a profit during the reporting period, driven by enhanced sales in pharmaceuticals and medical devices [10]. Investment Insights - Analysts suggest that the TCM sector is poised for growth, driven by innovative products and strong brand recognition, particularly in high-value markets [7][8]. - The focus on stable cash flow to support R&D expenditures is expected to be a key strategy for TCM companies moving forward [7].

Core Viewpoint - The traditional Chinese medicine (TCM) sector is experiencing significant opportunities, driven by policy support and strong performance in the stock market [1][2]. Market Performance - On August 1, the A-share market saw a mixed performance with the Shanghai Composite Index down 0.37%, Shenzhen Component down 0.17%, and ChiNext down 0.24%, while over 3,300 stocks rose [1]. - The TCM sector witnessed a surge, with the Shenwan TCM Index rising by 1.78%, placing it among the top-performing secondary industry indices [2]. Policy and Industry Developments - The establishment of the Yangtze River Delta TCM Concept Verification and Achievement Transformation Center in Shanghai aims to enhance the commercialization of TCM research [2]. - The State Council's 2025 policy emphasizes the protection and utilization of TCM resources, indicating a supportive regulatory environment for the industry [2]. Company Performance - Notable companies such as Darentang, Jilin Aodong, and Buchang Pharmaceutical reported significant net profit growth, with Darentang's net profit expected to reach between 18.4 billion to 20 billion yuan, marking a year-on-year increase of 180% to 204% [4][5]. - Jilin Aodong anticipates a net profit of approximately 12.36 billion to 12.9 billion yuan, reflecting a year-on-year growth of 130% to 140% [5]. - Tianmu Pharmaceutical successfully turned a profit during the reporting period, driven by enhanced market strategies and sales [5]. Financial Highlights - The following companies reported substantial net profit growth in the first half of 2025: - Darentang: 19.2 billion yuan, up 192% [6] - Jilin Aodong: 12.63 billion yuan, up 135% [6] - Buchang Pharmaceutical: 5.98 billion yuan, up 158.41% [6] - The overall performance of TCM companies indicates a strong recovery and growth trajectory, supported by favorable market conditions and policy initiatives [4][5].

Core Viewpoint - Jilin Aodong Pharmaceutical Group Co., Ltd. has developed a dual-driven path of "old medicine new making" and "one ginseng drives regional prosperity" over 42 years, focusing on innovation while inheriting traditional practices [1] Product Positioning - The company emphasizes product standards as a passport to high-end markets, striving to enhance product quality and brand positioning [2] Product Development - The "Anshen Bnona Liquid," a compound traditional Chinese medicine, has captured an 80% market share since its inception in 1983, transitioning from local to national standards [3] - The company has expanded its ginseng product line, with 44 medicinal products and over 100 functional foods, projecting a revenue of over 200 million yuan from ginseng products in 2024 [3] Source Foundation - Jilin Aodong adheres to the principle that quality raw materials ensure quality products, with significant investments in GAP-certified bases for deer and local medicinal materials [4] - The company has established over 6,000 acres of medicinal material bases and has received multiple quality certifications for its ginseng and deer products [4] Technological Empowerment - The introduction of an intelligent extraction control system in 2003 has automated the production of Anshen Bnona Liquid, ensuring product safety and consistency [5] - The same technological advancements are being applied to the ginseng sector, enhancing production efficiency and quality assurance [5] Brand Development - The company has successfully leveraged national advertising and sports sponsorships to enhance brand recognition, with plans to expand its ginseng products into international markets [6][7] Research and Development - Continuous R&D efforts have demonstrated the efficacy of Anshen Bnona Liquid in treating neurodegenerative conditions, with recent studies highlighting the potential of deer antler in Alzheimer's treatment [8][9] - The company is also exploring new applications for ginseng saponins in treating various health conditions, aiming to enter the billion-yuan market for brain health [9] Policy Environment - Jilin Aodong benefits from favorable policies that support the development of traditional Chinese medicine and the enhancement of its deer breeding practices, ensuring long-term growth and competitive advantage [10][12]

Group 1: Research Breakthroughs - The study published in "Nature Aging" reveals that extracellular vesicles from antler blastema progenitor cells can reverse bone loss and mitigate aging-related phenotypes in mice and macaques, effectively making the biological age of macaques younger by an average of 2.14 years [1][4] - The research highlights the unique regenerative capabilities of deer antlers, which are the only mammalian organs that can completely regenerate periodically, making them an ideal model for studying aging and regeneration [2][3] Group 2: Company Developments - Jilin Aodong, the largest deer product processing company in China, has over 60 years of experience in breeding deer and has continuously developed and researched deer antler products, including the "Anshen Bnona Liquid," which is now supported by scientific evidence for its traditional efficacy [5][6] - The company has achieved significant market share in the traditional Chinese medicine sector, holding 60%-70% of the market for calming and brain-enhancing products, with annual sales exceeding 700 million yuan [6][8] Group 3: Policy and Industry Trends - The Jilin provincial government has issued a development plan for the deer industry (2025-2029), encouraging the exploration of classic formulations and modern biotechnological applications to enhance the efficacy of deer products [8][9] - Jilin Aodong aims to integrate traditional deer antler value with cutting-edge biotechnology, positioning itself to capture a significant share of the brain health market, which is projected to be worth hundreds of billions [7][9]